Machine Learning Assisted Real-Time Label-Free SERS Diagnoses of Malignant Pleural Effusion due to Lung Cancer.
Source check: Source checked. Not independent scientific confirmation.
Finding: PLS-DA classifies SERS spectra from malignant lung-cancer versus control pleural fluid; Methods describes spectra and classifier, Results reports measured diagnostic performance. Results reports 85% accuracy, 87% sensitivity, 83% specificity, AUC 0.93 on study samples; validation is within-cohort and narrow.
Technology: PLS-DA classifies SERS spectra from malignant lung-cancer versus control pleural fluid; Methods describes spectra and classifier, Results reports measured diagnostic performance.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- PLS-DA classifies SERS spectra from malignant lung-cancer versus control pleural fluid; Methods describes spectra and classifier, Results reports measured diagnostic performance.
- Test and result
- Results reports 85% accuracy, 87% sensitivity, 83% specificity, AUC 0.93 on study samples; validation is within-cohort and narrow.
- Limitation / still unknown
- Validation basis and its limits are stated in Results.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/articles/PMC9688333?pdf=render · https://pubmed.ncbi.nlm.nih.gov/36354448/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.